Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Accured Expenses (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Change in Accured Expenses data on record, last reported at -$400000.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 92.28% year-over-year to -$400000.0; the TTM value through Dec 2025 reached -$1.3 million, down 345.92%, while the annual FY2025 figure was -$1.3 million, 345.92% down from the prior year.
  • Change in Accured Expenses reached -$400000.0 in Q4 2025 per VRCA's latest filing, up from -$501000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.5 million in Q3 2023 and bottomed at -$5.2 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $481950.0, with a median of $496500.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 581.82% in 2022, then soared 7011.11% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$700000.0 in 2021, then skyrocketed by 110.29% to $72000.0 in 2022, then skyrocketed by 7011.11% to $5.1 million in 2023, then tumbled by 201.17% to -$5.2 million in 2024, then soared by 92.28% to -$400000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$400000.0 in Q4 2025, -$501000.0 in Q3 2025, and -$1.4 million in Q2 2025.